Dr. Leslie Fischer, Ph.D., J.D. is a Principal Patent Attorney at Novartis Pharmaceuticals Corp. in East Hanover, NJ.  She focuses on global patent prosecution, freedom to operate, regulatory exclusivity, licensing, contractual negotiations, and due diligences.  Her technology area of expertise is biopharmaceutical products, particularly for the treatment of autoimmune diseases.  Dr. Fischer is also Novartis Pharmaceutical’s designated liaison to the United States Patent Office (USPTO), a role created to enhance the relationship, facilitate dialogue, and share information between these entities.  She also teaches mechanical patent claim drafting as an adjunct professor of law at Seton Hall Law School, in Newark, NJ. 

Prior to joining Novartis in 2007, Dr. Fischer was an associate attorney at Fitzpatrick, Cella, Harper and Scinto in New York, during which time she provided detailed opinion work for a broad range of clients, consulted on biotechnology litigation, and performed pharmaceutical and biotechnology patent prosecution.

Dr. Fischer holds a J.D. from Rutgers University, and a Ph.D. in Biochemistry from Thomas Jefferson University in Philadelphia. Her Ph.D. thesis focused on the interaction of Bone Morphogenetic Proteins and Wnts during mouse limb development, with her work appearing in Osteoarthritis and Cartilage, the Journal of Cellular Biochemistry, and the Journal of Biological Chemistry.

Dr. Fischer has appeared as a speaker and panelist in numerous public forums.  Most recently, she presented on patent subject matter eligibility at the 12th Annual Advanced Patent Law Institute, which was sponsored by the University of Texas School of Law and the USPTO, March 9-10, 2017, Alexandria, VA.  For the past three years, she has also acted as co-chair of American Conference Institute’s “Advanced Summit on Life Sciences Patents" meeting, which is held yearly in New York, NY.